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Lymphocryptoviruses such as Epstein-Barr virus (EBV) cause persistent infections in human and non-
human primates, and suppression of the immune system can increase the risk of lymphocryptovirus
(LCV)-associated tumor development in both human and non-human primates. To enable LCV infection
as a non-clinical model to study effects of therapeutics on EBV immunity, we determined the genomic
DNA sequence of the LCV from cynomolgus macaque, a species commonly used for non-clinical testing.
Comparison to rhesus macaque LCV and human EBV sequences indicates that LCV from the cynomolgus
macaque has the same genomic arrangement and a high degree of similarity in most genes, especially
with rhesus macaque LCV. Genes showing lower similarity were those encoding proteins involved in
latency and/or tumor promotion or immune evasion. The genomic sequence of LCV from cynomolgus
macaque should aid the development of non-clinical tools for identifying therapeutics that impact LCV
immunity and carry potential lymphoma risk.
& 2015 Elsevier Inc. All rights reserved.Introduction
Lymphocryptovirus (LCV) comprises a genus of double-
stranded DNA gammaherpesviruses that cause lifelong infection
in their respective primate hosts. The LCV that infects humans,
Epstein-Barr virus (EBV), is recognized as a pathogen associated
with several diseases, including infectious mononucleosis (IM),
nasopharyngeal carcinoma, and lymphomas (Hislop et al., 2007;
Okano and Gross, 2012; Thorley-Lawson and Gross, 2004). The LCV
in each primate species has likely co-evolved with that species, yet
LCV from different primates are grossly similar (Veovodin and
Marx, 2009). LCV from the rhesus macaque (Macaca mulatta, an
Old World primate), the most extensively studied non-human
primate LCV, appears to be nearly identical to EBV in terms of
tissue tropism and pathogenesis (Veovodin and Marx, 2009;
Moghaddam et al., 1997; Rivailler et al., 2004; Wang et al., 2001).
Consistent with these similarities in biology, rhesus LCV and EBV
share similar genomes: they have an identical genomic arrange-
ment, all ORFs are present in both viruses, and a high degree of
sequence similarity exists across a large number of genes (RivaillerDevelopment, Pﬁzer Global
, Eastern Point Road, Groton,
. Kamperschroer).et al., 2002a). In particular, most rhesus LCV genes encoding
structural proteins and proteins involved in viral replication are
well conserved, whereas those encoding proteins involved in
maintaining viral latency, cellular transformation, or immune
evasion are more divergent (Rivailler et al., 2002b; Fogg et al.,
2005; Jiang et al., 2000; Ohashi et al., 2012; Peng et al., 2000;
Rivailler et al., 2002; Tellam et al., 2007).
The genetic organization of LCV from the marmoset (Callithrix
jacchus, a New World primate) is also similar to EBV, although
there are some differences in genetic repertoire (Rivailler et al.,
2002). While there is sequence information available for individual
LCV genes from other non-human primate species, complete
genomic sequences are not available for the LCV from non-human
primates besides the rhesus macaque and the marmoset. Because
of the host species speciﬁcity of LCVs, phylogenetic relationships
between different LCVs may mirror those between the host spe-
cies, although this is not absolute (Ehlers et al., 2003; Ehlers et al.,
2010; Lacoste et al., 2010).
Although EBV infection is associated with IM, lymphomas, and
other diseases, infection is asymptomatic in the vast majority of
healthy individuals. The risk of developing EBV-related disease is
greatly increased with immunosuppression, and transplant
patients receiving immunosuppressive drugs as well as HIV/AIDS
patients have increased EBV-associated lymphoproliferative dis-
ease or lymphomas (Clarke et al., 2013; Engels et al., 2008, 2011).
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associated lymphoproliferative disorders (Rivailler et al., 2004;
Kahnt et al., 2002; Marr-Belvin et al., 2008; Page et al., 2013;
Schmidtko et al., 2002).
Therapeutic immune suppression is intended for transplant or
autoimmune indications, and many therapeutics may increase the
risk of EBV-related disease, yet there are limited tools to evaluate
effects on LCV immunity non-clinically. The cynomolgus macaque
(Macaca fascicularis) is the non-human primate species most
commonly used for non-clinical drug testing, and for biologics it is
often the only species that shows cross-reactivity. LCV infection of
cynomolgus monkeys is being explored as a non-clinical model to
assess the potential for therapeutics to increase EBV-related dis-
ease (Kamperschroer et al., 2012, 2014a, 2014b; Kawabata et al.,
2012); however, current tools for using this model are immature.
The genomic sequence of cynomolgus LCV has been suggested as a
key piece of information needed to further develop the model
(Kawabata et al., 2012).
To allow for the development of additional tools to detect LCV
(e.g. LCV-speciﬁc ISH probes, PCR primers/probes, or antibodies) as
well as LCV-speciﬁc immune responses (e.g. immunogenic pep-
tides/proteins and multimers for detecting LCV-speciﬁc T cells), we
have sequenced the putative LCV genome from cynomolgus
macaque (for simplicity, referred to in this report as cynomolgus
LCV). Speciﬁcally, we sequenced LCV from cynomolgus macaque
from the island of Mauritius because animals from this location
are often used for non-clinical testing, and because this population
may be particularly useful for evaluating antiviral immune
responses (T cell responses) due to its restricted MHC diversity
(Budde et al., 2010; Burwitz et al., 2009; Krebs et al., 2005;
O'Connor et al., 2007, 2010). The resulting sequence information
should facilitate basic research on lymphocryptoviruses as well as
aid the development of cynomolgus LCV as a model of EBV in the
setting of drug development.Fig. 1. Preparation of LCV genomic DNA for sequencing. (A) Isolation of LCV DNA using p
LCV-transformed LCL, embedded in agarose, and subjected to PFGE. The discrete band
digestion. (B) Determination of LCV DNA enrichment. The relative copy number of LCV
using a quantitative PCR assay speciﬁc for the BALF2 gene of cynomolgus LCV and for
RPL13A are shown. The BALF2 (LCV speciﬁc) Ct values for the duplicate unenriched LC
samples were 15.44 and 15.63. The Ct values for the RPL13A endogenous cellular control
for the enriched LCV samples.Results
To determine the genomic sequence of cynomolgus macaque
LCV, DNA was isolated directly from a lymphoblastic cell line (LCL)
known to be infected with LCV (Kamperschroer et al., 2014). In
addition, the LCV genome from the LCL cells was enriched using
pulse-ﬁeld gel electrophoresis (PFGE) and subsequent isolation of
the band (at an apparent size of 150 kb) corresponding to the
putative LCV genomic DNA (Fig. 1A). This enrichment resulted in
approximately 50-fold higher abundance of LCV genome (lower
Ct values) as measured by a quantitative PCR assay speciﬁc for the
BALF2 gene of cynomolgus LCV (Kamperschroer et al., 2014),
whereas the RPL13-A gene from the host cell line decreased in
abundance following enrichment (Fig. 1B). These two DNA tem-
plates were then used for next generation sequencing (NGS) to
determine the cynomolgus LCV genomic DNA sequence.
Of the 16,106,748 paired-end reads from the unenriched LCL
NGS sample, a total of 189, 088 (0.59%) reads mapped to the LCV
genome for an average coverage of 113X. The NGS analysis of the
enriched LCV sample had 11,816,996 paired-end reads of which
2,853,785 reads (12.1%) mapped to LCV, with an average coverage
of 1704X. With both the unenriched and the enriched samples,
coverage was fairly regular across the genome (see Supplementary
Fig. S1). Of note, however, there was an overabundance of cover-
age in the region around the internal repeat (IR) region 1, or IR1,
consistent with there being multiple sequence repeats in this
region. From the differences in percent LCV mapped reads, the LCV
enrichment was calculated to be 22-fold, further supporting the
quantitative PCR data indicating substantial enrichment of the
viral DNA.
The resulting assembled genome of LCV from cynomolgus
macaque is 154,158 bp. The genomic arrangement (shown in
Fig. 2) is nearly identical to LCV from rhesus macaque as well as to
EBV (Fig. 2 and Rivailler et al. (2002)). A comparison of the
assembled cynomolgus LCV genome to all other viral whole gen-
omes at NCBI revealed that the cynomolgus LCV genome is mostulse-ﬁeld gel electrophoresis (PFGE). High molecular weight DNA was isolated from
migrating at approximately 150 kb (boxed) was excised and puriﬁed by β-agarase
genome in unenriched and PFGE-enriched (as in A) DNA samples was determined
the cellular endogenous control gene, RPL13A. Ampliﬁcation plots for BALF2 and
L DNA samples were 17.00 and 17.18, and the Ct values for the LCV-enriched DNA
gene were 22.7 and 22.9 for the duplicate unenriched samples and 26.91 and 26.94
Fig. 2. Genomic arrangement of LCV from cynomolgus macaque. Blue and green arrows indicate protein coding genes on the plus and minus strands, respectively. Light blue arrows show the non-coding mRNA EBER1 and EBER2
genes as well as a genomic region encoding genes for which the precise protein coding regions have not been deﬁned by sequence similarity. Light gray bars indicate repeat regions, for which the precise number of repeats is
undeﬁned.
C.K
am
perschroer
et
al./
V
irology
488
(2016)
28
–36
30
Fig. 3. Similarity comparisons of cynomolgus LCV to other LCV genomes. (A) The cynomolgus LCV genome sequence was compared to all available lymphocryptovirus whole
genome sequences, and a similarity tree was generated from resulting alignments. Aligning sequences were: Callitrichine herpesvirus 3 (NC_004367.1), Human herpesvirus 4
(NC_007605.1), Human herpesvirus 4 type 2 (NC_009334.1), and Macacine herpes virus 4 (NC_006146.1). (B) The cynomolgus LCV genome was aligned to the rhesus LCV
genome (Macacine herpesvirus 4, NC_006146) using MEGABLAST.
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cynomolgus LCV genome is compared to other whole LCV gen-
omes, rhesus LCV (Macacine herpesvirus 4) is identiﬁed as closest
relative (Fig. 3A). Alignment of cynomolgus LCV to rhesus LCV
shows a high degree of similarity between the two sequences over
the majority of the genomes (Fig. 3B). However, there do appear to
be regions of dissimilarity near the right end of the genome, most
notably at approximately 123–133 kbp and 149–153 kbp. The for-
mer region contains the repetitive region IR4 and a block of
sequence with no protein coding sequences (CDS). Since no pro-
teins are encoded here, this region may have diverged at a higher
rate than the rest of the genome. This region is also ﬂanked by LF3
(Fig. 2), which exhibits low sequence similarity between viral
species (Rivailler et al., 2002). The latter region at approximately
149–153 kbp does not contain any proteins and may also have
diverged to a greater extent.
Although the sequence was generally consistent across differ-
ent reads, there was heterogeneity observed at a number of
nucleotide positions, suggesting the presence of at least one viral
variant (Supplementary Table S1). Although the nucleotide dif-
ferences were not assigned to speciﬁc variants, there were pre-
dominantly two populations of nucleotides at a given position,
suggesting two predominant variants. The heterogeneity did show
selectivity for speciﬁc genes. Speciﬁcally, it was observed in mul-
tiple EBNA genes, and was more prevalent (i.e., at multiple
nucleotide positions) in EBNA-3C, BOLF1, BFRF2, EBNA-1, and the
predicted EBNA-LP gene.
Similar to LCV from other species, there were several repeat
regions present in the cynomolgus LCV genome. The internal
repeats IR2 and IR4 (OriLyt) mapped from nucleotide positions
23,758 to 25,258 and 124,958 to 126,458 respectively. The IR3
mapped between 79,608 and 80,158 and contained an over-
representation of G residues, resulting in discontinuous repetitive
features when aligned to itself. While there were only short
(100 bp) repeats at the right end of the cynomolgus LCV genome
sequence, the best similarity with the last 1000 bp this region was
to the last 1000 bp of the rhesus LCV genome (81% identity).
Similarly, the ﬁrst 2500 bp of the cynomolgus LCV genome
showed highest similarity to the ﬁrst 2500 bp of the rhesus LCV
genome (78% identity). Based on this similarity we assigned these
regions as the start and end of the cynomolgus LCV genome. The
largest repeat region maps to residues 11,953 to 20,006 and cor-
responds to the large W repeat region (IR1) previously reported in
the rhesus LCV (NC_006146.1) and marmoset LCV (NC_004367.1)
genomes (Rivailler et al., 2002; Rivailler et al., 2002). Because thesize of this repeat region and the arrangement of the repeats was
difﬁcult to determine using the NGS data, multiple high ﬁdelity
“long” PCR products spanning the IR1 region were generated using
different primer sets, their approximate sizes were determined by
gel electrophoresis, and they were cloned and sequenced using
PacBio. Based on the initial NGS data as well as the PacBio
sequencing of the PCR products, there are 2.7 repeats of a 3000
nucleotide sequence in IR1 of cynomolgus LCV, which shows high
similarity to the IR1 repeat sequence of rhesus LCV. This number of
repeats in the cynomolgus LCV IR1 is lower than the 5.7 repeats
reported for rhesus LCV IR1 and the 11.3 repeats reported for IR1
from the B95-8 isolate of EBV (Rivailler et al., 2002). The terminal
repeat (TR) region in rhesus LCV has 4 repeats (Rivailler et al.,
2002) whereas NGS of cynomolgus LCV identiﬁes a single repeat.
The difference in the TR region may represent technical limitations
of NGS of repetitive regions (Treangen and Salzberg, 2012), rather
than a true difference between the different species of LCV.
Based on sequence and positional similarity to ORFs in other
LCV species as well as Sanger-based sequencing of cloned cDNA
products, 76 open reading frames were identiﬁed in the cyno-
molgus LCV genome. Global alignments of encoded proteins to
proteins from LCV in the common marmoset (Callitrichine her-
pesvirus 3; NC_004367.1 ), EBV (Human herpesvirus 4 type 2;
NC_009334.1), and the rhesus macaque (Macacine herpesvirus 4;
NC_006146.1) revealed protein similarities ranging from 99.7%
identity to essentially no (3.6%) identity (Fig. 2, Table 1, and Sup-
plementary Table S2). In general, a high degree of similarity was
observed in lytic phase structural proteins or DNA replication
proteins; as examples, BALF5, BBLF4, BDLF1, and BcLF1 showed
98–99% identity with rhesus LCV and 93–97% identity with
EBV. Latency proteins such as those encoded by the EBNA genes
showed lower similarity; EBNA-1, EBNA-2, and EBNA‐3A‐C showed
70–89% identity with rhesus LCV and 33–44% identity with
EBV (Table 1). Immunomodulatory proteins might be expected to
also have lower similarity and this was observed in some genes;
however, the colony stimulating factor (CSF)-1 receptor homolog
BARF1 had a very high degree of similarity, showing 99.7% identity
with rhesus LCV and 96% identity with EBV (Table 1). Similarity of
cynomolgus LCV would be expected to be higher with rhesus LCV
than with EBV, given the evolutionary relationships between the
hosts. This was true in most cases, but some proteins showed
greater similarity to EBV than to rhesus LCV. As examples, BcRF1, a
protein of unknown function, showed 72% identity with rhesus
LCV and 82% identity with EBV, and the uncharacterized protein
Table 1
Cynomolgus LCV genes and percent protein identity/similarity to EBV, rhesus LCV, and marmoset LCV proteinsa.
Gene Genome location Callitrichine herpesvirus 3 (Marmoset
lymphocryptovirus)
Human herpesvirus 4 type 2
(Epstein-Barr virus type 2)
Macacine herpesvirus 4 (Rhesus
lymphocryptovirus)
% Id % Sim % Id % Sim % Id % Sim
LMP2A 149362..1768 55.6 70.9 61.0 76.4
LMP2B 178..391 57.0 75.2 62.0 78.9
BNRF1 1825..5781 43 58.6 78 87.1 93.7 96.2
BCRF1 9490..10005 84.2 90.1 92.7 94.9
EBNA-2 20870..22672 16.8 26 34.7 44.9 76.6 81.3
BHRF1 25905..26480 26.9 40.1 69.6 83.8 96.9 96.9
BFLF2 27540..28493 -
complement
49.8 64.6 86.2 91.2 95 96.2
BFLF1 28506..30080 -
complement
51.6 64.1 87 92.4 97.1 97.5
BFRF1 30440..31432 45.8 58.6 80.4 84.9 94.8 95.2
BFRF2 31336..33147 37.5 47.8 79 84.6 95.4 96.5
BFRF3 33071..33583 40.9 52.6 74 80.2 97.6 98.2
BPLF1 33624..42950 -
complement
37.2 50.8 70.8 78.9 88.5 91.5
BOLF1 43000..46710 -
complement
41.6 54.1 72.5 78.4 90.8 92.9
BORF1 46709..47800 49.5 64.5 88 90.8 97.2 98.1
BORF2 47864..50332 57.3 70.2 87.3 93.5 98.4 99.1
BaRF1 50345..51253 72.8 84.4 95.7 97.4 99.7 99.7
BMRF1 51346..52563 44.4 59.5 88.6 91.6 97.3 97.8
BMRF2 52568..53641 47.4 66.6 85.7 93 98.6 99.2
BMLF1 54252..55649 -
complement
38.9 54.3 79.1 85.6 96.3 97.2
BSLF1 55846..58470 -
complement
50.4 65.6 86.7 92.3 97.5 97.9
BSRF1 58513..59178 61.4 74.9 88.7 93.2 98.6 99.5
BLLF3 59241..60080 -
complement
51.8 64.5 87.8 92.8 97.8 98.2
BLRF1 60154..60462 45.2 55.8 74.5 80.4 98 98
BLRF2 60533..61024 42.2 52.4 79.1 87.1 93.9 95.1
gp350 61041..63407 -
complement
27.3 43.1 49.7 60.3 89 92
BLLF2 61181..61600 -
complement
8.7 13.7 57.4 71.6 87.8 92.8
EBNA-3A 63540..66359 12.3 22.4 34.4 46.8 70.1 77.1
EBNA-3B 66545..69247 15 23.1 33.2 42.9 72.8 77.9
EBNA-3C 69378..72903 11.7 18.5 35.1 47.7 84 87.9
BZLF2 72953..73618 -
complement
37 52 81.2 88.3 94.1 97.7
BZLF1 73718..74811 -
complement
29.9 46 72.4 79.6 93.9 96.4
BRLF1 75022..76827 -
complement
41.4 56.2 79.3 85 91.9 93.7
BRRF1 76826..77755 47.1 65.2 88.4 95.5 93.2 96.8
BRRF2 77942.79447 27.3 44 59.1 69.3 93.4 96
EBNA-1 79483.81042 27.3 34.9 44.4 50.9 89 91.5
BKRF2 81125.81539 51.7 62.2 81 88.3 97.1 97.8
BKRF3 81520.82287 75.4 88.3 96.5 98 98.8 99.6
BKRF4 82298.83020 28.7 40.6 61.8 68.9 88.4 91.3
BBLF4 83062.85485 -
complement
65.6 77.3 93.1 95.8 97.9 98.4
BBRF1 85430.87274 71.4 82 92.7 95.4 98.4 98.4
BBRF2 87177.88013 58.3 75.3 92.1 95.3 96.8 98.2
BBLF2_3 88010.88624 -
complement
23 34.1 77.7 84.2 65.7 67.8
BBRF3 90392.91625 54.5 75.4 90.7 93.6 96.8 98
BBLF1 92022.92246 -
complement
39.7 59 77.3 86.7 87.8 93.2
BGLF5 92201.93631 -
complement
70.4 81.1 92.6 95.6 97.9 98.7
BGLF4 93597.94889 -
complement
61.4 77.2 92.6 96.7 98.1 98.8
BGLF3 95216.96214 -
complement
46.8 63.2 88.9 93.4 97.3 98.5
BDRF1 96213.101659 37.3 44 94.1 96.5 98.6 99
BGLF2 97138.98148 -
complement
62.5 78.9 88.1 94 91.7 95.5
BGLF1 98129.99634 -
complement
38.4 52.1 76.3 82.4 92.4 94.6
BDLF4 99604.100326 -
complement
50.4 65.4 82.5 86.7 95 95
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Table 1 (continued )
Gene Genome location Callitrichine herpesvirus 3 (Marmoset
lymphocryptovirus)
Human herpesvirus 4 type 2
(Epstein-Barr virus type 2)
Macacine herpesvirus 4 (Rhesus
lymphocryptovirus)
% Id % Sim % Id % Sim % Id % Sim
BDLF3 101670.102506 -
complement
6.9 10.2 48.6 56.7 59.1 69.8
BDLF2 102571.103782 -
complement
25.1 40.5 67.2 75.3 92.8 95.3
BDLF1 103792.104697 -
complement
70.1 84.1 96.7 99 99.3 100
BcLF1 104713.108858 -
complement
76 85.9 95.9 98.3 99 99.6
BcRF1 108857.111136 43.7 55.8 82.2 86.4 72.1 73.8
BTRF1 111123.112334 57.9 72.5 90.8 96 97.3 98.3
BXLF2 112331.114451 -
complement
39.4 57.2 85.6 92.4 87.8 93.4
BXLF1 114453.116276 -
complement
49.5 62.3 89.6 92.4 97.2 98.2
BXRF1 116275.117024 40.7 53.9 82.3 86.7 94 96
BVRF1 116834.118540 51.8 66.5 86 91.2 96.7 97.5
BVRF2 119345.121195 42.7 53.1 75.7 81.2 93.5 94.7
BILF2 121230.121976 -
complement
19.6 32.4 71.4 81.9 81.4 88.5
LF3 124720.125040 -
complement
6 7.4 8.6 10.2 5.7 6.5
LF2 132172.133461 -
complement
60.2 73.2 93 96.3 97.4 98.6
LF1 133422.134816 -
complement
32.2 45 76.5 83.4 91.6 94.4
BILF1 134825.135781 -
complement
35.8 55 79.2 85.8 83 88.7
BALF5 136495.139542 -
complement
74 83.8 95 97.4 98.7 99.6
ECRF4 138022.138996 13.9 22.9 82.3 83.9
BALF4 139545.142139 -
complement
60.6 74.5 86.5 91.4 93.8 95.8
BALF3 142126.144180 -
complement
56.7 71 87.8 91.1 98.4 99
BALF2 144196.147585 -
complement
69.5 81.9 94.4 96.5 94.5 95
BALF1 147670.148218 -
complement
28.4 45.9 84.6 95.1 96.7 98.4
BARF1 148318.148983 7.6 12 73.3 83.7 87.8 93.7
BNLF2b 149790.150086 -
complement
5.9 8.2 71.3 83.2 65.3 82.7
BNLF2a 150092.150274 -
complement
3.6 5.4 58.3 76.7 58.3 70
a Protein accession numbers are given in Supplementary Table S1. Protein sequences for EBNA-LP and LMP-1 were not determined. Id¼ identity; Sim¼ similarity.
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with EBV (Table 1).
Determination of the precise intron/exon boundaries and
therefore the predicted protein sequences for two latency proteins,
EBNA-LP and LMP1, was precluded by the difﬁculty of NGS
sequencing through repetitive regions (Treangen and Salzberg,
2012), the low similarity with related species, the presence of
multiple exons in these genes, and the inability to generate and
clone cDNA products for these genes. However, these genes were
present within the genomic DNA sequence, as evidenced by
similarity to the corresponding rhesus LCV genes in the same
genomic locations (data not shown). A homolog of BARF0, a CTL
target for EBV (Kienzle et al., 1998), was not identiﬁed in cyno-
molgus LCV. Interestingly, there is a region in the cynomolgus LCV
genome at position 143,329 to 143,811 which could encode a
BARF0 with 95% identity to the rhesus LCV BARF0; however, this
putative cynomolgus LCV BARF0 gene has a stop codon after
amino acid residue 10, suggesting that the gene encodes a trun-
cated protein.
In the cynomolgus LCV, the BBLF2/BBLF3 protein is synthesized
as a single polypeptide. This fusion is unlike the state reported for
rhesus LCV (Rivailler et al., 2002), but it has been reported in otherLCVs, including EBV (Dolan et al., 2006). It is not known whether
this is a true difference between the rhesus LCV and cynomolgus
LCV genomes or whether the reported rhesus LCV BBLF2/BBLF3
proteins are actually synthesized as a single protein.
Recently Skalsky et al. reported that, like EBV, rhesus LCV
expresses more than 30 microRNAs (miRNAs) (Skalsky et al., 2014).
We used the precursor miRNA sequences from this virus as listed
at miRBase to search for homologs within the cynomolgus LCV
genome. Of the 36 sequences examined, we found regions of
greater that 95% identity to rlcv-mir-rL1-1, rlcv-mir-rL1-2, rlcv-
mir-rL1-17, & rlcv-mir-rL1-18 (data not shown). No other regions
with greater that 70% identity were found. Further investigation is
required to determine if these four candidate miRNAs or other
miRNAs are expressed.Discussion
To our knowledge, the results presented here represent the ﬁrst
reporting of the sequence of the LCV genome from cynomolgus
macaques. Overall, there was a high degree of similarity observed
between cynomolgus LCV and rhesus LCV (and to a lesser extent,
C. Kamperschroer et al. / Virology 488 (2016) 28–3634EBV), as would be expected given the close evolutionary rela-
tionship between the hosts. It was also expected that latency
proteins or immune evasion proteins would show less similarity
(Rivailler et al., 2002; Rivailler et al., 2002), and this was also true
in most cases. However, the CSF-1 receptor protein encoded by
BARF1 showed very high similarity with both rhesus LCV and EBV.
BARF1 is a homolog of the colony stimulating factor (CSF)-1
receptor that can block CSF-1 signaling. It may promote B cell
transformation in rhesus monkeys, but is not required for viral
replication or for B cell transformation (Ohashi et al., 2012). Also,
while BARF1 is a CTL target in humans (Martorelli et al., 2008) and
therefore may be under immune pressure, BARF1 has not been
identiﬁed as a CTL target in rhesus monkeys (Orlova et al., 2011).
Given these observations, the high degree of similarity of BARF1 is
surprising and merits further investigation.
Some cynomolgus LCV proteins, such as BcRF1 and BNLF2b,
displayed higher similarity to EBV than they did to rhesus LCV,
suggesting the possibility that these genes underwent selection
driven by factors other than host evolution. However, this obser-
vation could also relate to differences between LCV in cynomolgus
macaques and rhesus macaques, or properties of the population of
cynomolgus macaques from Mauritius, which could result from
founder selection, differences in pathogen-driven selective pres-
sure, or other factors. Particularly for the immune evasion genes
and the latency genes involved in B cell transformation, it will be
of interest to determine how LCV from cynomolgus macaques
from different geographic locations compare to each other and to
other primate species.
Based on the sequence reported here, the cynomolgus LCV
BARF0 gene encodes a truncated protein due to a stop codon after
amino acid residue 10. BARF0 is a target for cytotoxic T-cells
against Epstein-Barr virus (EBV) (Kienzle et al., 1998), yet it does
not appear to be critical for EBV replication or B cell transforma-
tion (Wilkie et al., 2014). Although changes acquired during long
term culture of the virus are possible, it is also possible that
selective pressure and/or species isolation has resulted in the early
truncation of this protein in the Mauritian cynomolgus LCV we
have sequenced. Such truncation of genes or gene products has
been observed in other lymphocryptoviruses and in other her-
pesviruses in other species, and may represent changes ﬁxed by
selective pressure (Wilkie et al., 2014; Aoki et al., 2007; Cheung
et al., 1998).
The IR1 of EBV, rhesus LCV (Rivailler et al., 2002), and cyno-
molgus LCV (this report) contains coding sequences for EBNA-2
and EBNA-LP, and the number of repeats has been shown to cor-
relate with efﬁciency of transformation (Tierney et al., 2011). The
IR1 from our cynomolgus LCV sequence contains 2.7 major
repeats, which is different from the 5.7 repeats reported for the
IR1 of rhesus LCV. The number of IR1 repeats in different EBV
isolates or even different cell lines derived from the same donor
can be highly variable (Tierney et al., 2011; Allan and Rowe, 1989),
so differences in repeat numbers are not unexpected. The impact
of IR1 repeat number on viral transformation with cynomolgus
LCV has not been determined, but inference from EBV would
predict an IR1 repeat number of 2.7 to be suboptimal for inducing
transformation (Tierney et al., 2011).
Our primary goal for sequencing the cynomolgus LCV was to
enable the development of tools to monitor both LCV as well as
immune responses against LCV in the cynomolgus macaque in the
setting of drug development. Past efforts to develop such tools
have been hampered in some cases by a lack of knowledge of gene
or protein sequences. For example, we have generated overlapping
peptide pools based on rhesus LCV sequences in order to detect T
cell responses against cynomolgus LCV proteins (eg. EBNA-1,
EBNA‐3A‐C, LMP1, BZLF1), but were unable to detect T cell
responses (L.O. and C.K., unpublished observations). The lack ofresponses for at least some of the proteins may have been due to
sequence differences in the synthesized peptides compared to the
bona ﬁde cynomolgus LCV sequences, particularly for proteins
with greater divergence. Cynomolgus LCV sequence will circum-
vent these complications and will allow the generation of a
number of tools, including quantitative PCR or ISH assays to detect
virus or viral gene expression, peptides for stimulating T cell
responses, and peptide-MHC multimers for detecting Ag-speciﬁc T
cells. The LCV sequence from Mauritian cynomolgus macaques
may be particularly valuable for studying anti-LCV T cell immunity
due to the highly restricted MHC diversity in that population
(Budde et al., 2010; Burwitz et al., 2009; Krebs et al., 2005;
O'Connor et al., 2007, 2010). The small number of MHC haplotypes
in the Mauritian population may enable the selection of a rela-
tively small number of immunogenic peptides that are able to
selectively stimulate either CD4 T cell or CD8 T cell responses in
most, if not all, individual animals, without the need for MHC
haplotyping and selection of animals. Once immunogenic peptides
are deﬁned, multimers for direct staining of LCV-speciﬁc T cells
can also be generated, and a small pool of multimers may allow for
detection of responses in all animals. The ability to measure LCV-
speciﬁc T cell responses may also have broader utility beyond
evaluating the potential for EBV-related disease, in that LCV-
speciﬁc T cell responses could be used in a general way to
directly monitor effects of therapeutics on cell mediated immunity
in monkeys.
Methods for detecting the LCV genome, measuring LCV gene
expression, and evaluating immunity to LCV will allow for the
further development of LCV infection in cynomolgus macaques as
a non-clinical model for EBV in humans. This model is currently
being explored as a way to evaluate the risk that a candidate
therapeutic will impact immunity against LCV and increase the
risk of EBV-related disease in humans (Kamperschroer et al., 2012;
Kamperschroer et al., 2014; Kamperschroer et al., 2014; Kawabata
et al., 2012). The genomic sequence of LCV from the cynomolgus
macaque will greatly facilitate these efforts.Materials and methods
LCL generation
Mauritius-origin adult cynomolgus macaques (Macaca fascicu-
laris), obtained from Charles River Laboratories (Houston, TX) and
housed at Pﬁzer in Groton, CT were used for all experiments.
Housing and all procedures were conducted in accordance with
the guidelines of the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. Peripheral blood
mononuclear cells (PBMC) were used to generate an LCV-
transformed lymphoblastic cell line (LCL), as previously descri-
bed (Kamperschroer et al., 2014). Brieﬂy, PBMCs were isolated
from a healthy three-year-old female monkey and cultured at
106 cells/mL in ﬂat bottomed 96-well plates (Costar) for approxi-
mately 3 weeks in complete media comprised of RPMI 1640
medium supplemented with 10% FBS, 2 mM Glutamax, penicillin/
streptomycin/amphotericin B, 0.1 mM non-essential amino acids,
and 1 mM sodium pyruvate (all from Invitrogen). Cells were then
cultured for approximately 12 weeks in the presence of complete
media containing 2 ug/mL cyclosporine to prevent immune cell
control over LCV-infected B cells. The LCL surviving at the end of
this culture period was characterized to conﬁrm the presence of
LCV (Kamperschroer et al., 2014) and cryopreserved. After thaw-
ing, the LCL was cultured for 3 weeks in complete media and then
DNA was isolated from the LCL for sequencing.
C. Kamperschroer et al. / Virology 488 (2016) 28–36 35DNA extraction and isolation
High molecular weight genomic DNA for sequencing was iso-
lated directly from a cynomolgus monkey LCV-transformed LCL
using Qiagen's genomic tip and genomic DNA buffer set (Qiagen
Inc. Valencia, CA) according to the manufacturer's protocol. In
addition, pulse-ﬁeld gel electrophoresis (PFGE) of agarose-
embedded DNA samples was performed using the CHEF-DR III
PFGE system (Bio-Rad Laboratories Hercules, CA) at 6 V/cm at
14 °C. Switch time was ramped from 50 to 90 s for 19 h. Following
band visualization with ethidium bromide, the discrete band
migrating at approximately 150 kb was excised and puriﬁed by
β-agarase digestion ( New England BioLabs Inc., Ipswich, MA)
followed by isopropanol precipitation.
Quantitative PCR
Real time PCR assays for detection of cynomolgus monkey LCV
(BALF2) genomic DNA as well as for the cellular endogenous
control gene RPL13A.R.A. (RPL13A, used for normalization) were
performed as described previously (Kamperschroer et al., 2014).
Brieﬂy, unenriched and PFGE-enriched DNA samples isolated from
a cynomolgus monkey LCV-transformed B cell line (see DNA
extraction and isolation section above) were run in duplicate on the
ABI 7900HT Real Time PCR system with SDS v2.4 Enterprise data
acquisition software (ABI). Samples were analyzed using RQ
Manager software (ABI) and were normalized to their endogenous
controls, and all samples were compared to the unenriched
genomic DNA calibrator sample.
Whole-genome sequencing
Cynomolgus monkey LCV DNA samples were submitted for
whole genome sequencing to BGI (Hong Kong). A custom low
template input library preparation and a combination of standard
Illumina and in-house protocols were used to produce multiplexed
paired-end libraries of extracted DNA with an average insert size
of 200 bp. Sequencing was performed on the Illumina HiSeq
2000, generating 100 bp paired-end reads. For the unenriched
DNA sample, a set of fastq reads were generated using the SOAP
alignment tool that consisted of all those reads which were not
similar to the cynomolgus monkey genome (GCA_000222185.1).
This set of ﬁltered reads and the set of unﬁltered reads from the
enriched LCV DNA sample were used for virus genome assembly.
Sequence analyses
Initial sequence assembly was performed by aligning the
direct/ﬁltered sample reads to rhesus macaque LCV (Macacine
herpesvirus 4; NC_006146.1) using bwa (Skalsky et al., 2014). A
consensus sequence was generated using samtools (Garcia-Alcalde
et al., 2012). The direct/ﬁltered reads were also assembled using
the de novo assembly tool Abyss (Cheung et al., 1998). De novo
assembly sequences generated by Abyss were aligned to the con-
sensus sequence using BLAST (Orlova et al., 2011). Alignments
were used to manually ﬁll-in mismatches and gaps. Further
manual annotation was performed after bwa alignment with the
enriched virus sample reads and BLAST alignment with Abyss
assembled enriched virus sample sequences. Coverage calculations
and visualizations were generated using Qualimap (Garcia-Alcalde
et al., 2012). All visualizations of read sequences to the generated
cynomolgus macaque LCV genome were performed using the
Integrated Genome Viewer from the Broad Institute (Aoki et al.,
2007). Single exon ORFs were identiﬁed from the ORFs generated
from a six-frame translation of the viral genome with the highest
BLAST similarity to rhesus macaque LCV (Macacine herpesvirus 4)proteins. Additional multi-exon ORFs were identiﬁed by aligning
protein and mRNA sequences from the rhesus LCV genome to the
completed cynomolgus virus genome. Final visualization of the
genome and protein coding sequences was perfomed using gview
(Allan and Rowe, 1989). Global sequence alignments between
cynomolgus LCV proteins and other herpesvirus protein was per-
formed using the EMBOSS tool ‘stretcher’ (Tierney et al., 2011).
Inter-viral genome comparisons were performed using blastn at
the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi) using the
“Reference genomic sequences (refseq_genomic)” database while
limiting the organisms to lymphocrytovirus (txid:10375).
High ﬁdelity PCR for IR1 sequence determination
Multiple primers ﬂanking the IR1 region were designed and
used in conjunction with the Long Amp High Fidelity PCR system
(New England Biolabs, or NEB) to amplify multiple PCR products
from genomic DNA isolated from the LCL infected with LCV. A ﬁnal
DMSO concentration of 2% allowed for ampliﬁcation of the
approximately 8.6 kb IR1 region. Multiple PCR products were
pooled and then cloned using the NEB PCR cloning kit (NEB).
Plasmid containing the 8.6 kb IR1 insert was then used for PacBio
sequencing (by Expression Analysis and BGI Hong Kong). The
resulting sequence was ﬁltered for cloning vector.
Cloning and sequencing to determine protein coding sequences not
determined by NGS
Cynomolgus macaque LCL cDNA and the Long Amp PCR system
containing a ﬁnal DMSO concentration of 2% was used for ampli-
ﬁcation with speciﬁc primers for cynomolgus LCV EBNA-2, EBNA-
LP, LMP1, LMP2A & LMP2B cDNA sequence. The resulting PCR
products were cloned via the NEB PCR Cloning Kit (NEB) and then
subjected to Sanger sequencing (by Genewiz).
Sequence accession number
The genomic sequence of LCV from cynomolgus macaque
reported here can be accessed at accession number KP676001.Acknowledgments
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